These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 24345653)
1. Telmisartan reduced abdominal circumference and body weight with decreasing triglyceride level in patients with type 2 diabetes and metabolic syndrome. Kakuma T; Gotoh K; Masaki T; Itateyama E; Abe N; Yoshimatsu H Obes Res Clin Pract; 2010; 4(2):e83-e162. PubMed ID: 24345653 [TBL] [Abstract][Full Text] [Related]
2. Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. Shimabukuro M; Tanaka H; Shimabukuro T J Hypertens; 2007 Apr; 25(4):841-8. PubMed ID: 17351377 [TBL] [Abstract][Full Text] [Related]
3. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. Sugimoto K; Kazdová L; Qi NR; Hyakukoku M; Kren V; Simáková M; Zídek V; Kurtz TW; Pravenec M J Hypertens; 2008 Jun; 26(6):1209-15. PubMed ID: 18475159 [TBL] [Abstract][Full Text] [Related]
4. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Usui I; Fujisaka S; Yamazaki K; Takano A; Murakami S; Yamazaki Y; Urakaze M; Hachiya H; Takata M; Senda S; Iwata M; Satoh A; Sasaoka T; Ak ND; Temaru R; Kobayashi M Diabetes Res Clin Pract; 2007 Aug; 77(2):210-4. PubMed ID: 17240472 [TBL] [Abstract][Full Text] [Related]
5. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Yamagishi S; Takeuchi M Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852 [TBL] [Abstract][Full Text] [Related]
9. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation. Yamagishi S; Takenaka K; Inoue H Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710 [TBL] [Abstract][Full Text] [Related]
10. New treatment strategies for patients with hypertension and insulin resistance. Kurtz TW Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944 [TBL] [Abstract][Full Text] [Related]
11. Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. Vecchiet J; Ucciferri C; Falasca K; Mancino P; Di Iorio A; De Caterina R Antivir Ther; 2011; 16(5):639-45. PubMed ID: 21817185 [TBL] [Abstract][Full Text] [Related]
12. Telmisartan and metabolic syndrome after heart transplantation. Luknar M; Goncalvesova E; Lesny P; Fabian J Clin Transplant; 2010; 24(1):36-9. PubMed ID: 19222503 [TBL] [Abstract][Full Text] [Related]
13. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan. Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876 [TBL] [Abstract][Full Text] [Related]
14. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. Wago T; Yoshimoto T; Akaza I; Tsuchiya K; Izumiyama H; Doi M; Hirata Y Hypertens Res; 2010 Aug; 33(8):796-801. PubMed ID: 20555330 [TBL] [Abstract][Full Text] [Related]